Quick Facts: Uses and Benefits

Condition	Treatment Focus
Chronic Asthma	Long-term maintenance of symptoms
Exercise-Induced Bronchoconstriction	Prevention of breathing difficulty
Seasonal Allergic Rhinitis	Relief of associated nasal symptoms
Perennial Allergic Rhinitis	Management of year-round nasal symptoms

---

What Лукаст Treats: Main Uses and Benefits

Лукаст (Montelukast) is a prescription medication utilized in the management and prophylaxis of several chronic inflammatory conditions. It is indicated for the long-term maintenance treatment of asthma in adults and pediatric patients above a specified age. This treatment approach aims to reduce the frequency of asthma symptoms and help improve overall patient breathing function over time.

The medication is also prescribed for the acute prevention of exercise-induced bronchoconstriction (EIB). This use is intended to minimize the likelihood of breathing difficulties that may arise from physical activity.

Furthermore, Лукаст may offer relief from the symptoms associated with allergic rhinitis, which includes both seasonal (often called hay fever) and perennial (year-round) allergic responses. It helps alleviate nasal symptoms such as sneezing, runny nose, and nasal congestion associated with these conditions. For allergic rhinitis, its use is generally reserved for patients who have an inadequate response to or cannot tolerate alternative therapies. It is important to note that this medication is not intended for use in treating sudden, acute asthma attacks.

This section outlines the officially documented population eligibility and non-eligibility for Лукаст (Montelukast), based strictly on regulatory documents.

Contraindications and Restrictions

Classification	Restriction
Contraindicated	Patients with known hypersensitivity to Montelukast or any component of the formulation.
Prohibited Use	Treatment of acute asthma attacks (for chronic control only).
Conditional Use	Use for allergic rhinitis is reserved for patients with an inadequate response or intolerance to alternative therapies.

Age and Physiological Eligibility

Eligibility is strictly defined by the minimum age required for each approved indication. Use is considered not established in patients below these age limits:

• Asthma: Approved for patients ge 12 months of age.
  • Not established in children younger than 12 months.
• EIB Prevention: Approved for patients ge 6 years of age.
  • Not established in children younger than 6 years.
• Allergic Rhinitis: Minimum age is ge 6 months (Perennial AR) or ge 2 years (Seasonal AR).

Special Populations

• Pregnancy and Lactation: Use during both pregnancy and breastfeeding is generally allowed only if considered clearly essential by a healthcare provider.
• Hepatic Impairment: No dosage adjustment is required for mild-to-moderate impairment; however, use is not established for patients with severe hepatic impairment due to a lack of clinical data.
• Renal Impairment: No dosage adjustment is necessary for patients with renal insufficiency.

Interactions with other medicines and products for Lukas are primarily defined by pharmacokinetic modulation and specific co-administration restrictions documented in official regulatory labels.

Interaction Profile

Co-administration with other Montelukast-containing products is explicitly restricted to avoid excessive exposure, as stated in prescribing information.

Pharmacokinetic Interactions

The drug is a substrate for metabolism by CYP2C8, CYP2C9, and CYP3A4 enzymes. Co-administration with the potent inhibitor Gemfibrozil significantly increases Montelukast systemic exposure by approximately 4.4-fold. Conversely, co-administering with strong CYP inducers, such as Rifampicin or Phenytoin, may lead to a decrease in Montelukast plasma concentrations. Regulatory documents confirm the absence of clinically important interactions with medicinal products such as Warfarin, Theophylline, and oral contraceptives.

Pharmacodynamic and Formulation Restrictions

Patients with documented aspirin sensitivity must continue to avoid aspirin and Non-Steroidal Anti-Inflammatory Agents (NSAIDs) while using the product. Furthermore, the chewable tablet formulation contains phenylalanine and carries a specific cautionary note for patients with Phenylketonuria (PKU). Administration rules require that an additional dose for exercise prevention not be taken within 24 hours of a scheduled daily dose.

This structure identifies specific agents that alter exposure and mandates defined restrictions to ensure regulatory compliance across different patient scenarios.

How Лукаст Works

Лукаст functions as a leukotriene receptor antagonist. Its action involves the competitive binding to the CysLT1 receptor, a key biological target expressed on various cells within the respiratory tract, including smooth muscle cells and inflammatory cells such as eosinophils and mast cells.

This specific molecular interaction prevents the engagement of endogenous cysteinyl leukotrienes (LTC4, LTD4, and LTE4) with the CysLT1 receptor. By blocking the binding site, Лукаст effectively modulates the downstream signal transduction cascade initiated by leukotrienes.

The resulting intracellular process involves the inhibition of Ca^2+ influx and the subsequent reduction of IP3 production, which are typical effects mediated by the receptor. The system-level physiological consequence of this targeted antagonism is a decrease in airway smooth muscle contraction and a reduction in microvascular leakage associated with inflammatory processes in the pulmonary system.

How to Use Лукаст

The administration of Montelukast is strictly oral, utilizing dosage forms that include film-coated tablets, chewable tablets, and single-dose oral granules. The frequency of use for maintenance therapy is once daily, with the timing determined by the condition being managed. For patients with asthma, the dose is typically taken in the evening. If the medication is prescribed solely for allergic rhinitis, the dose may be taken in the morning or evening. Continuous administration is a requirement for long-term maintenance treatment, even during periods when the patient is asymptomatic.

Dosing strength is stratified by age, ranging from 4 mg (for pediatric patients 6 months to 5 years old) to the standard adult dose of 10 mg (for individuals 15 years and older). Chewable tablets and film-coated tablets may be taken with or without food. If administering the oral granules, the dose must be mixed with a spoonful of soft, cold food or 5 mL of baby formula, and the full dose must be administered within a 15-minute window of opening the packet. If a scheduled daily dose is missed, the next scheduled dose is taken at the usual time; an extra dose must not be taken to compensate for the missed administration.

Evidence for Long-Term Maintenance of Chronic Asthma

Montelukast was studied for chronic asthma maintenance in Randomized Controlled Trials (RCTs). These studies were used in research exploring how symptoms change over time across a wide range of patients, including pediatric groups. Studies monitored physiological outcomes such as objective lung function measures ( FEV1) and outcomes related to physical discomfort by tracking daily symptom scores and the frequency of exacerbations. Findings describe patterns observed in the studies related to how symptoms evolved in the observed populations, compared to placebo.

When research examined comparative evidence against standard treatments like inhaled corticosteroids (ICS), findings reported distinctions. The certainty remains low regarding the establishment of equivalence to these first-line maintenance therapies for many measured outcomes. Long-term outcomes extending beyond one year are not well characterized across diverse patient populations.

Research Evidence for Preventing Exercise-Induced Bronchoconstriction (EIB)

The use of Montelukast for preventing EIB was evaluated in controlled clinical studies, primarily short-term RCTs. Research examined outcomes reflecting daily functioning by measuring the drop in forced expiratory volume in one second ( FEV1) after a standardized exercise test. Even though findings describe patterns observed in the controlled settings, research is ongoing. Evidence is limited regarding the durability of these patterns when the medicine is taken continuously, and research does not determine whether an individual will respond similarly during spontaneous, real-world activity.

Evidence for Allergic Rhinitis (Seasonal and Perennial)

Montelukast was studied for allergic rhinitis, including conditions where symptoms may vary in intensity seasonally or year-round. Research was applied in studies examining patient-reported experiences, exploring outcomes related to physical discomfort by monitoring nasal symptoms like congestion and sneezing. Comparative evidence is lacking when assessing the medicine against other treatments for allergic rhinitis. For this condition, findings indicate its use often appears to be reserved for patients who have an inadequate response to or cannot tolerate alternative therapies. Data for the sustained measurement of perennial, year-round symptoms remain insufficient.

Common questions about Лукаст (FAQ)

Q: Is Lukast the same as Montelukast?

A: Lukast is the brand name used for the active substance Montelukast (formulated as Montelukast sodium). Official documents confirm that Montelukast is the active substance responsible for the drug's intended action as a Leukotriene Receptor Antagonist.

Q: How does Lukast differ from common antihistamines?

A: Lukast belongs to a distinct pharmacological group known as Leukotriene Receptor Antagonists (LTRAs). It works by blocking the effects of inflammatory signals called leukotrienes. This mechanism is different from that of common antihistamines, which primarily work by blocking histamine receptors.

Q: What are the main side effects of Lukast?

A: According to official adverse reaction data, common reported effects include upper respiratory infection, headache, nausea, and vomiting. Regulatory agencies also highlight the potential for serious, rare neuropsychiatric events, which involve changes in mood and behavior.

Q: What is the best time of day to take Lukast?

A: For the long-term treatment of asthma, the dose is instructed to be taken in the evening. This timing is based on how efficacy was demonstrated in clinical studies for asthma control. If the medication is prescribed solely for allergic rhinitis, it may be taken in the morning or the evening.

Q: How can Lukast help with exercise-induced asthma (EIA)?

A: For the prevention of exercise-induced bronchoconstriction (EIB), a single dose is administered at least two hours before the activity. Regulatory guidance specifies that an additional dose is not to be taken within 24 hours of a scheduled daily dose.

Q: Does Lukast only help with seasonal allergies or perennial ones too?

A: Regulatory documents indicate that the medicine is approved for the relief of symptoms related to both seasonal allergic rhinitis (SAR) and perennial allergic rhinitis (PAR). Perennial allergic rhinitis refers to symptoms that persist year-round.

Q: Why is it sometimes necessary to take Lukast in the evening?

A: Taking the dose in the evening is the specific instruction for the long-term, chronic management of asthma. This timing aligns with the administration schedule used in the clinical studies that demonstrated its efficacy for controlling asthma symptoms.

Q: What should I do if my condition worsens while taking Lukast?

A: This medicine is not indicated for treating sudden, acute asthma attacks. Official safety guidance emphasizes that appropriate rescue medication be kept available. If symptoms worsen, or if new neuropsychiatric symptoms are observed, regulatory guidance recommends contacting a healthcare provider immediately.

Q: How long does it take for Lukast to start working?

A: Clinical pharmacology studies indicate that the concentration of the active ingredient in the body typically reaches its peak approximately three to four hours after oral administration in adults. This time period indicates when the concentration of the active ingredient is typically highest in the bloodstream.

Q: Does Lukast help with all types of cough?

A: The medicine has specific regulatory approvals, meaning it is indicated for use in asthma, exercise-induced bronchoconstriction (EIB), and allergic rhinitis. It is not approved for the general treatment of all types of cough.

Q: Is it true that Lukast can affect mood?

A: Official regulatory warnings highlight the potential for serious neuropsychiatric events. These events can include changes in mood and behavior, such as depression, agitation, and anxiety, as a potential risk.

Q: Can Lukast cause sleep problems?

A: Official reports indicate that sleep problems are listed among the possible neuropsychiatric adverse events. Reported symptoms include insomnia (trouble sleeping), unusual dreams, and nightmares.

Q: Does Lukast affect the ability to drive?

A: Official documents generally state that the medicine has no or negligible influence on the ability to drive or use machinery. However, regulatory information notes that individuals have reported experiencing dizziness or drowsiness.

Q: Can Lukast be taken during pregnancy?

A: Regulatory guidance specifies that use during pregnancy is generally allowed only if considered clearly essential by a healthcare provider. The determination of essential need is made by the prescribing healthcare professional.

Q: Is Lukast addictive?

A: Regulatory documents do not indicate that the medicine causes addiction or physical dependence. It is approved for the chronic, long-term management of inflammatory conditions.

Q: Can Lukast be taken while breastfeeding?

A: Official guidance states that only small amounts of the active medicine pass into breast milk. Use is generally allowed only if considered clearly essential by a healthcare provider, and use during this time is determined based on essential need.

Q: Is Lukast sold without a prescription?

A: Lukast is designated as a prescription-only medication. The product is classified as a prescription-only medication.

Q: Is it true that Lukast can cause nightmares?

A: Nightmares and other dream abnormalities are listed among the reported, though uncommon, neuropsychiatric adverse reactions. These effects are documented in official safety information.

Q: Does Lukast affect blood test results?

A: Regulatory documents indicate that the medicine has been associated with changes in certain laboratory tests. This includes reports of elevated liver enzymes and, rarely, an increase in eosinophils (a type of white blood cell) during treatment.

Q: Does Lukast help with sinusitis?

A: This medicine is indicated for seasonal and perennial allergic rhinitis (hay fever). It is not approved for the treatment of general sinusitis, which is a distinct condition.

Q: Can Lukast interact with herbal supplements?

A: The medicine is metabolized by certain liver enzymes (CYP2C8, CYP2C9, and CYP3A4). Co-administration with strong enzyme inducers, which can include certain supplements, may affect drug exposure. This topic is best discussed with a healthcare professional.

Q: What is the maximum length of treatment for Lukast?

A: Lukast is indicated for the long-term, chronic management of conditions like asthma and perennial allergic rhinitis. Regulatory documents specify that continuous administration is required for maintenance treatment.

Q: Does Lukast help with shortness of breath?

A: The medicine is approved for the long-term control and prophylaxis of conditions like asthma and EIB. Its anti-inflammatory mechanism is intended to stabilize the airways and help reduce the swelling that can cause symptoms like shortness of breath.

Q: Does taking Lukast affect the immune system?

A: The medicine is classified as an anti-inflammatory agent. Regulatory documentation also notes rare post-marketing reports of systemic eosinophilia, sometimes consistent with Churg-Strauss Syndrome, which involves processes that are sometimes associated with the use of the medicine.

Q: Can Lukast cause headaches?

A: Headache is listed in official documentation as a common adverse reaction associated with the use of this medicine. It is one of the more frequently reported effects in clinical trial data.

Q: What should I do if a rare side effect of Lukast appears?

A: Official safety guidance recommends that patients contact a healthcare professional immediately if they experience any new or worsening adverse reactions. Healthcare providers are responsible for reporting adverse events to the relevant regulatory agency.

Q: Is there official information about Lukast overdose?

A: Yes, official prescribing information includes data on the management of accidental overdose. Reported symptoms following overdose are generally consistent with the known adverse reactions of the medicine.

Storage and Disposal of Lukast (Montelukast)

Montelukast must be stored under controlled conditions to maintain its stability. The medicine should be stored at or below 25°C and away from excessive heat. To protect the active ingredient from degradation, it must be kept in its original package and protected from both light and moisture.

All forms of this medicine must be stored out of the sight and reach of children.

For the oral granules, any mixture with food or liquid must be administered immediately (within 15 minutes) and cannot be stored. Unused or expired Lukast must be disposed of in accordance with local regulatory requirements.